1. Which DOAC is a factor IIa inhibitor?

2. For treatment of VTE in patient with CrCl < 30 mL/min, which DOACs should be avoided?

3. Compared to warfarin, large analyses of DOAC use in patients with renal impairment showed which results for DOACs?

4. In patients with cancer, which DOACs are potential options to treat VTE or Afib?

5. An 89-year-old woman presents to the emergency department with new onset shortness of breath. She is diagnosed with atrial fibrillation. Her BMI is 19.5 kg/m2. She has a history of hypertension, hyperlipidemia, heart failure with reduced ejection fraction, and chronic kidney disease (SCr: 0.8 mg/dL, CrCl 35 mL/min). Her current medications include metoprolol succinate 50 mg daily, atorvastatin 40 mg daily, lisinopril 5 mg daily, spironolactone 12.5 mg daily, and dapagliflozin 10 mg daily. Which DOACs would pose the lowest bleed risk for this patient?

6. A 57-year-old male presents to the emergency department with pain, swelling and redness on his calf. He recently traveled from the US to Asia and back for work. The provider makes a diagnosis of new proximal DVT. His BMI is 44.9 kg/m2. What DOAC would you recommend be initiated for treatment of a new VTE in this patient?

7. A 62-year-old woman with a FVL hypercoagulable state presents to her primary care clinician with new onset swelling and redness in her thigh. She has developed VTEs on warfarin in the past and is asking if there are any alternatives. Would you suggest a DOAC as an alternative for her?

8. In patients with renal dysfunction, which of the following impact bleeding risks with DOAC?

« Return to Activity